JF Augusto

Néphrologue, CHU d'Angers

[ASN Publications @asnpublications]

The 2025 #ASNJASN #ASNCJASN and #ASNKidney360 Trainees of the Year are Benoît ​Brilland, Thomas Bais, and Yuhei Noda! This prize celebrates the best article submitted to each journal by a trainee as the first author.

See more about the contest and this year's winners: https://t.co/HCI1FU26IH

[Groupe Spiesser @GroupeSpiesser]

Bravo à Priscille Traversat et au groupe Spiesser pour ce joli travail concernant le devenir après transplantation rénale des patients atteints de vascularites à anticorps anti-MBG présenté à la #SFNDT2024

[JF Augusto @FrancoiAugusto]

@AudemardVerger Bravo Alexandra!

[hannah kaminski @hKminski]

Bravo à tous les nouveaux PUPH et MCUPH de Néphrologie! @MaanaouiMehdi @mohamadzaidan @camillecohen @BenoitBrilland @SebastienRubin @manondekeyser @AntoineLanot @emmanuelesteve
@mathieulegendre

[Valentin-ℳ @ValentinMaisons]

Chouette session #SNO #Vascularites à Angers où la douceur de vivre n’est pas une légende ☀���
Merci à l’orga @MaineAnjouReg @FrancoiAugusto @FLavainne et aux supers orateurs (@AudemardVerger , @TerrierBen, @LucileFigueres…) 👏🏻

[Maine-Anjou Research Group @MaineAnjouReg]

CXCR2, CCR4, CD20… specifics PET tracers have been developed and some studies already published/ongoing about their abilities to diagnose/predict active vasculitis… we need to apply this to assess kidney inflammation in #ANCA #glomerulonephritis! @Jmtarkin #vasculitisBCN2024

[Maine-Anjou Research Group @MaineAnjouReg]

Reinforced anti-pneumococcal vaccination in #anca vasculitis (#FVSG PNEUMOVAS trial): better response to pneumococcal serotype (especially Arm2) and acceptable safety profil. Looking for the long term infection data now 🤞🏻. @TerrierBen #vasculitisBCN2024

[Maine-Anjou Research Group @MaineAnjouReg]

Post-hoc PEXIVAS analysis: no effect of reduced GC dose on kidney recovery. Faster kidney recovery with PLEX but no sustained effect beyond 3 months.
1️⃣ real PLEX effect vs convection effect?
2️⃣ how about stratification by histological class? @odlerb #vasculitisBCN2024

[Maine-Anjou Research Group @MaineAnjouReg]

Results of the open label TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab. @DrPeterMerkel #vasculitisBCN2024

[Maine-Anjou Research Group @MaineAnjouReg]

Questions remaining:
▶️ anti MPO specific CAR-T cells instead of CD19 CAR-T cells ? To preserve the regulatory fraction of B cells
▶️ how long will the effect last? ie which time point for next injection / RTX relay ?
#vasculitisBCN2024

[Maine-Anjou Research Group @MaineAnjouReg]

Animal model of CAR-T cells in #ANCA vasculitis: it almost looks easy to implement! And efficacy looks great too! Next step: patients? Dr D. Lodka & @AdrianSchreibe8 #vasculitisBCN2024

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

#SGLT2 inhibition in primary/secondary forms of glomerulonephritis

▶️https://t.co/D27HdW4fVf

[Katalin Susztak @KSusztak]

Angiotensinogen RNA interference to lower BP. The new era of RNA therapeutics might be here. https://t.co/0aWDxilShA

[NDT @NDTsocial]

Association between kinetic of anti-neutrophil cytoplasmic antibody, renal survival and relapse risk in ANCA-glomerulonephritis
➡️ANCA kinetics may help identify patients with a smouldering disease
Read more here👇
📖https://t.co/todltXwHbo
@MaineAnjouReg

[Sautenet Bénédicte @Sautenet]

Session concours des internes : modèle prédictif décès pour les vascularite à ANCA @com_SFNDT #SFNDT2022

[SFNDT @com_SFNDT]

🥇Concours des internes
Toujours une session où on assiste à d’excellentes présentations 👏🏻👏🏻👏🏻
#SFNDT2022

[Francois JOURET @francois_jouret]

⁦@com_SFNDT⁩ : Bravo aux lauréats du Concours des Internes #sfndt2022 : N. Fage, C. Gerontitis & E. Gouin 🥂

[Maine-Anjou Research Group @MaineAnjouReg]

What do we know about prognostic kidney lesions in #ANCA #vasculitis ? A thread. 🧵1/x

[Maine-Anjou Research Group @MaineAnjouReg]

@Vasculitis2022 Want to know more about complement alternative pathway in ANCA vasculitis? Find our full review here: https://t.co/NCvVb2fjwj